Ozempic for Alzheimer's? Novo Nordisk's $9.2 billion lottery ticket
Published on: Oct. 17, 2025, 7 a.m. | Source: Livemint
Novo Nordisk's Alzheimer's trial really is like a lottery ticket. If it wins, the company gains a transformational new market and billions in revenue. If it loses, the core diabetes and obesity business is strong enough to limit the downside.
